Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Avid Bioservices is a biotechnology business based in the US. Avid Bioservices shares (CDMO) are listed on the NASDAQ and all prices are listed in US Dollars. Avid Bioservices employs 321 staff and has a trailing 12-month revenue of around $134.2 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $16.00 |
|---|---|
| 52-week range | $11.30 - $22.83 |
| 50-day moving average | $14.61 |
| 200-day moving average | $16.01 |
| Wall St. target price | $22.33 |
| PE ratio | 10.1131 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.68 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $16 from 2023-01-26
| 1 week (2023-01-20) | -2.74% |
|---|---|
| 1 month (2022-12-28) | 18.43% |
| 3 months (2022-10-28) | -9.81% |
| 6 months (2022-07-28) | -21.41% |
| 1 year (2022-01-28) | -8.20% |
|---|---|
| 2 years (2021-01-28) | 13.56% |
| 3 years (2020-01-28) | 140.60% |
| 5 years (2018-01-26) | 340.77% |
Valuing Avid Bioservices stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avid Bioservices's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Avid Bioservices's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, Avid Bioservices shares trade at around 10x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Avid Bioservices's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.2 million.
The EBITDA is a measure of a Avid Bioservices's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $134.2 million |
|---|---|
| Operating margin TTM | 3.27% |
| Gross profit TTM | $36.6 million |
| Return on assets TTM | 0.74% |
| Return on equity TTM | 101.81% |
| Profit margin | 88.13% |
| Book value | $2.91 |
| Market capitalisation | $1.1 billion |
TTM: trailing 12 months
We're not expecting Avid Bioservices to pay a dividend over the next 12 months.
Avid Bioservices's shares were split on a 1:7 basis on 9 July 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Avid Bioservices shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Avid Bioservices shares which in turn could have impacted Avid Bioservices's share price.
Over the last 12 months, Avid Bioservices's shares have ranged in value from as little as $11.3 up to $22.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avid Bioservices's is 1.8455. This would suggest that Avid Bioservices's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Avid Bioservices, Inc. , a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
